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Abstract: Background: Oftentimes, persistent post traumatic headache (PPTH) and migraine are
phenotypically similar and the only clinical feature that differentiate them is the presence of a mild or
moderate traumatic brain injury (mTBI). The aim of this study is to describe the differences in brain
area and in biochemical cascade after concussion and to define the efficacy and safety of treatments
in use. Methods: Sources were chosen in according to the International Classification of Headache
Disorder (ICHD) criteria. Results: The articles demonstrated a significant difference between PPTH
and migraine regarding static functional connectivity (sFC) and dynamic functional connectivity
(dFC) in brain structure that could be used for exploring the pathophysiological mechanisms in
PPTH. Many studies described a cascade of neuro-metabolic changes that occur after traumatic
brain injury. These variations are associated to the mechanism occurring when developing a PPTH.
Conclusions: The state of art of this important topic show how although the mechanisms underlying
the development of the two different diseases are different, the treatment of common migraine is
efficacious in patients that have developed a post traumatic form.
Keywords: PTTH; migraine; persistent post-traumatic headache; pathophysiology; drugs;
traumatic-brain injury
1. Introduction
The International Classification of Headache disorder second edition (ICHD-2) [1] classifies
migraine as a primary headache disorder and post-traumatic headache (PTH) as secondary disorder
following a trauma or injury [2,3]. In particular, accordingly to the ICHD-2, the PTH has to onset within
seven days of traumatic injury to the head and/or neck or within 7 days of recovering consciousness
and the ability to report headache [4]. The third edition (ICHD-3) provides an implementation
of post traumatic headache adding the definition of persistent post-traumatic headache (PPTH).
Considerably, ICHD-3 divided PPTH in “Persistent headache attributed to moderate or severe
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traumatic injury to the head” and “Persistent headache attributed to mild traumatic injury to the
head” [5]. PTH is defined as acute if it develops during the first three months from trauma and as
persistent if this condition continues for longer than three months. It is important to note how PTH
occurs more easily after mild traumatic brain injury (mTBI) rather than moderate or severe TBI [6].
The clinical picture of PTH is more defined in subjects who report headache directly after the trauma
and with no history of migraine, even though it is not clear whether the trauma induces PTH or triggers
a pre-existing susceptibility to the migraine itself. Genetic predisposition might play a role, even if not
clear yet, in the onset of PPTH, considering that genes associated with familial hemiplegic migraine
type 1 and 2 induce an increase in neurological responses following trauma [7]. Several studies
have found that patients with a family history of headache exhibit a migraine phenotype more likely
compared to patients who do not have this familiar history [7–9]. The onset time of headache after
trauma can be useful for the diagnosis of PTH, considering that PTH, tension-type headache and
migraine symptoms are rather similar. ICHD-3 classification defined PTH a disorder characterized by
dizziness, fatigue, low ability to focus, motor and sleep disorder, anxiety, irascibility, memory problems
and changes in personality.
Patients with PTH present decreased activity levels due to the increase in headache pain,
cranial hyperalgesia and frequency of headaches crises [9]. Several factors might be involved in the
development of PTH, such as axonal injury, alteration in brain metabolism and/or haemodynamics and
genetic stability [10]. Moreover, accordingly to ICHD-3 classification, PPTH facilitates the misuse of
acute headache medication and unsuccessful preventative PTH pharmacological treatment could lead
to the medication-overuse condition (MO) [11]. Several studies conducted at the Danish Headache
Center have demonstrated that patients with PPTH met the criteria for MO, even if in many patients
the occurrence of headache did not improve following detoxification therapy [12,13]. In both cases
(PPTH and MO), the possibility that the treatments are ineffective and induce chronicity associated
with an overuse of medicaments could be sought in a non-optimal choice of the drug. The target of this
therapeutic failure to date seems to be the personalized approach [14]. This review points to evaluate
similarities and differences between migraine and PPTH, mainly considering the pathophysiology and
the pharmacological treatment.
2. Methods
The protocol for this systematic review has been designed following scoping searches of the
available literature. We also reviewed the reference lists of relevant primary articles. The review
process followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines.
2.1. Eligibility Criteria
Researches were considered eligible if they met the main criteria: randomized controlled trials
of adult participants diagnosed with post traumatic headache or persistent post traumatic headache
based on defined clinical criteria. Case–control studies, cohort studies or observational studies were
included as reference for this review. The exclusion criteria included unclearly defined study design,
target population or unclear results. The search was limited to articles on human subjects published
in English.
2.2. Source of Information
We systematically searched PubMed, Clinicaltrial and Researchgate until 2020. In addition,
research was carried out in specific scientific journals, finding potentially eligible studies for the writing
of this review: Headache; The Journal of Headache and Pain, Cephalalgia; Brain, Behavior, and Immunity;
Clinical Neurology and Neurosurgery; Neurology, among others.
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2.3. Search Strategy
The search was performed with the following search string: migraine; migraine therapy; migraine
AND persistent post-trauma headache; persistent post-trauma therapy; post traumatic headache OR
post-traumatic headache OR posttraumatic headache OR post traumatic migraine.
The electronic database search was supplemented with manual searches for published,
unpublished and ongoing randomized clinical trials (RCTs) in ClinicalTrials.gov. The search term was
“migraine and persistent post-traumatic headache.”
3. Results
Based on the research of the topics carried out, both original articles and reviews have been taken
into consideration. The focus is on articles dealing with the sensory differences between migraine and
PPTH, the neurophysiopathological and biochemical mechanisms and the pharmacological treatments.
The papers deal with experiments conducted both on animal models and people, including children
and adolescents.
3.1. Sensory Differences between Migraine and PPTH
Although migraine and PPTH present similar symptoms, only a few studies focused attention on
structural differences of the brain and on sensory profile that mark migraine and PPTH. Dumkrieger et
al. focused their attention on the differences in brain structure of patients suffering from migraine and
PPTH through a magnetic resonance imaging analysis. They analyzed the static functional connectivity
(sFC), the correlation between two signals in the region of interest (ROI), the dynamic functional
connectivity (dFC) or a connectivity/correlation that varies with time [15]. Significant differences in
sFC and dFC have been found between migraine and PPTH for the regions that participate in the
elaboration of pain, including the somatosensory region and the hypothalamus. The dFC was found to
be significantly correlated with the frequency of headache for the PPTH group and the intensity of pain
for the migraine group. sFC and dFC may therefore be useful for exploring the pathophysiological
mechanisms in PPTH and migraine [16]. Although it is hard to connect preclinical works and patients’
experience, visual stimuli could accentuate the migraine pain following the physiological connection
existing between the sensory pain processing region and the visual processing region. Levy et al.
have studied the sensory profile that characterized patient suffering of PPTH after TBI. The study was
conducted exclusively on male military personnel that have been grouped in three groups: PPTH
with migraine-like symptoms, PPTH with tension type headache and a last group with recurring
headache (TTH) [17]. The military with PPTH were further divided into two subgroups based on
intensity, localization, aggravating and mitigating factors for headaches: PPTH with a phenotype
similar to migraine (PPTH-migraine) group and PPTH similar to tension-type headache (PPTH-TTH)
group, respectively. Photophobia and stress without photophobia were considered as contributing
factors to a worsening of PPTH-migraine and PPTH-TTH (p = 0.006 and 0.0005, respectively); quiet
conditions and analgesic treatment contributed to significantly improve both PPTH-migraine and
PPTH-TTH (p = 0.049 and 0.02, respectively). Darkness and high volume were considered respectively
attenuating and worsening factors in both PPTH subgroups; similarly, head–neck pain and the
undefined localization of pain were reported as common factors in both types of headache [18].
3.2. Biochemical Alteration and Pathophysiology
Many studies have shown that the migraine pain pathway was triggered by the activation of
the trigemino-vascular system with the consequent release of several inflammatory neuropeptides.
TBI leads to both cellular and axonal metabolic alterations; these alterations follow an increase in
extracellular potassium concentrations, intracellular sodium and calcium levels, glutamate levels
(Figure 1). The restoration of ionic homeostasis requires such quantities of Adenosine Triphosphate
(ATP) as to reduce its resources on a cellular level. Consequently, the mismatch of supply and
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demand of ATP leads to an accumulation of lactate and oxidative stress status [19]. Increases in the
concentration of intracellular calcium trigger a cascade that leads to the collapse of the neurofilament
with disassembly of the microtubules. This results in axonal damage, known as secondary axotomy,
which might be part of the pathobiology of mTBI [20,21]. The neuroinflammation after TBI might
induce excitability of the central nervous system. The aura phase of migraine is thought to result from
cortical spreading depression (CSD), i.e., transient and self-propagating depolarization in glial cells
and neurons [22]. CSD leads to an increase in extracellular potassium concentration and glutamate
levels, which follows the activation of the trigeminal system [23,24] that is involved in migraine [25,26].
CSD upregulates matrix metal proteinases (MMPs) that exhibit elevated levels in migraine-induced
neuroinflammation or TBI [21,27]. The involvement of neuroinflammation in the pathophysiology
of PPTH has been demonstrated in preclinical studies in which N-acetyl cysteine (NAC) showed
anti-inflammatory and neuroprotective effects [28,29]. Treatment with NAC in military patients with
mTBI led to an 86% reduction in symptoms within seven days from the start of the treatment, compared
to placebo [30]. Although the pathophysiological mechanisms underlying migraine and PPTH are not
yet fully understood, several data suggest that migraine and its chronic forms as drug-induced migraine
showed altered levels of oxidative stress biomarkers and a reduction in antioxidant mechanisms [31].
Migraine patients have compromised mitochondrial metabolism, which affects both neural tissue
and the production of peripheral markers of oxidative stress [32]. Oxidative metabolism turns out to
be altered in patients with migraine, with or without aura, which also causes higher levels of lactic
acid [33] and a deficit of Nicotinamide Adenine Dinucleotide plus Hydrogen (NADH)-dehydrogenase
and cytochrome-c-oxidase [34]. As widely known, an abuse of migraine-drugs induces an increase
of neural excitability at the cortex and trigeminal system level, thus increasing the perception of
pain [35], increasing the abuse of drug and reducing the antioxidant capacity, as evidenced by
the reduction of the levels of Ferric Reducing Antioxidant Power (FRAP) plasmatic and total thiol
groups. This suggested reduction in antioxidant capacity could be in accordance with the altered
energy metabolism in the brain [32]. Hypothetically, PPTH could be associated with both a greater
mitochondrial dysfunction and an imbalance between the oxidative and antioxidant status, if compared
to migraine [31]. Human-induced migraine studies have determined that Calcitonin Gene Related
Peptide (CGRP) upregulate cyclic Adenosine Monophosphate (cAMP) levels, playing a key role in the
pathogenesis of both migraine and PPTH [36]. CGRP is a potent vasodilator [37,38], whose receptors
are present both in nerve fibers and in trigeminal neurons and in many areas involved in nociception
and pain processing [39,40]. The release of CGRP, following trigeminal stimulation, induces neurogenic
inflammation with mast cell degranulation [41], the release of pro-inflammatory modulators and the
alteration of the blood-brain barrier [42]. The stimulation of the trigeminal system induces an increase
in blood levels of CGRP causing attacks of migraine similar to those of spontaneous migraine [43].
Therefore, CGRP-dependent mechanisms are involved in central awareness in both migraine and
PPTH [44]. An increase in blood CGRP was also noted in a study of rodents suffering from drug abuse
migraines [45,46], linked to an increase in extracellular and cephalic allodynia (CA). In man, cephalic
allodynia has been found mainly in patients with PPTH [47], although similar results have also been
found with migraine [48]. Activation and sensitization of the trigeminal caudal nucleus (TCN) were
considered as mechanisms that underlie allodynia, and it is possible that the sensitization of thalamic
neurons is at the basis of extracellular allodynia [49].
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Figure 1. Metabolic alteration in Post Traumatic Headache disorder.
4. Treatment Approach
The approach to the treatment of PTH may vary considerably among clinicians.
Non-pharmacological approaches in patients with PTH with migraine-like features involve lifestyle
modifications, such as exercise, good sleep, hydration and management of stress or events triggering
migraine attacks. The pharmacological treatment for PTH uses acute or preventive medications typical
of primary headache disorders. The Food and Drug Administration did not approve treatments for
PTH with migraine phenotype with a high probable of unnecessary therapy, and the pharmacological
treatment may interfere with comorbidities such as depression and anxiety.
Regarding comorbidities, anxiety and depression were diagnosed in soldiers with TBI or
post-traumatic stress disorder (PTSD); in particular, a retrospective study evidenced that depression
was present in 30%–50% of military personnel with TBI or PTSD and anxiety episodes were reported
in 60% of subjects within two years from the trauma [50]. Furthermore, considering them individually,
in a study conducted by Chrisman et al., adolescents with a history of concussion had shown an
increased risk 3.3 times greater of receiving a diagnosis of depression than those without previous
medical history [51]. In the same way, states of anxiety are also linked to sleeping problems [51,52].
On the other hand, insomnia is associated with PTH as described by Jaramillo et al., observing that
27% of patients with PTH suffered from insomnia [52].
At present, the drug treatment of migraine offers a several kinds of remedies. Therapy should
have efficacy and durability to restore the normal activities and do not present adverse events that are
often associated with drug use [53].
4.1. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Drugs
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most represented drugs for migraine
treatment and the first choice for medication [53]. In patients affected by PTH, where intracranial
hemorrhage has been excluded, NSAIDs drugs such as ibuprofen or naproxen are often used for
treatment. Petrelli et al. have conducted a study on 79 subjects (mean age 12.9 years) with PTH.
The participants were divided into four groups on the pharmacological treatment: acetaminophen
(n = 20), ibuprofen (n = 20), combined treatment with acetaminophen and ibuprofen (n = 19) and
standard care (n = 20) without analgesic drugs. The combination treatment showed an efficacy of 79%,
61% for the ibuprofen group, 33% in the acetaminophen group and 21% in the standard care group.
However, the use of NSAIDs drugs should be limited in order to reduce the possible risk of incurring
in medication overuse (MO), while acetaminophen is used in subjects where the use of these drug
treatment is not recommended [54].
4.2. Triptans Drugs
Triptans, a family of tryptamine-based drugs, represent a class of abortive medication for the
acute therapy of migraine and cluster headache with proved efficacy [53]. The use of triptans, such as
sumatriptan and rizatriptan, is advised in patients who do not respond to anti-inflammatory drugs
and are characterized by migraine features [55] but are contraindicated in patients with vascular or
coronary disease due to their vasoconstrictive effects [2]. A study conducted on military personnel
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with PTH, reported that the use of triptans medication induces a reliable headache 2 h post-doses if
compared with military subjects that did not use triptans (p = 0.01). Although this is an observational
clinic-based non-controlled study, these drugs could be effective for aborting acute attacks in subjects
with PTH [56].
4.3. Tricyclic Antidepressants Drugs
Prophylaxis medications for migraine treatment are represented by Tricyclic antidepressant
(TCAs) drugs [53]. The use of TCAs is recommended in patients presenting insomnia and PTH.
Among the TCA drugs, amitriptyline is an effective antimigraine therapy, which induces sedation
but presents adverse events such as dizziness, dry eyes and mouth, constipation and increased
appetite and cardiac adverse events with onset arrhythmia and an extension of the QT interval [57].
The properties of amitriptyline include anti-anxiety and anti-depressant effects and sleep promoting
which are characteristics of PTH [56]. Couch et al. described the efficacy of amitriptyline compared
to the placebo group. In particular, the study showed a significant data regarding the treatment
with amitriptyline at 8 weeks (p = 0.031) and at 16 weeks (p = 0.043). Furthermore, the amitriptyline
group showed a significant decrease in headache frequency at 8 weeks if compared to the placebo
(p = 0.018) [58]. A recent phase 2 clinical trial (NCT01856270) described the efficacy of amitryptyline
in patients with mTBI. Participants, within the first 12 weeks after injury, were randomized into two
groups: an immediate group (n = 24), which began administration drug directly after recruiting
(one 10 mg capsule each evening), and an amitriptyline delayed group (n = 26), which began the
pharmacological treatment on the day 30 visit (one 10 mg capsule each evening). The standard dosages
were adjusted up to 25 mg during the second week and up to 50 mg during the third week of treatment.
Only 33 subjects arrived at the end of 90 days of the therapy management. The results did not show a
clarity preventive effect of amitriptyline for PTH disease [59].
4.4. Antiepileptics Drugs
Antiepileptic drugs are used as preventive treatment, including topiramate that can cause different
side effects such as sleepiness, paresthesias, weight loss, metabolic acidosis, memory and/or language
problems and renal dysfunction [60]. In a study conducted on military subjects with mild head
trauma, topiramate showed a significant reduction in PTH frequency for patients, 57% suffering from
chronic migraine and 31% presenting medication overuse. Results showed topiramate as an effective
prophylactic treatment with respect to low doses of TCAs [56].
4.5. Monoclonal Antibodies
Treatment with anti-CGRP monoclonal antibodies inhibits hypersensitivity to migraine pain
induced by glyceryl trinitrate (GTN), a known migraine factor [38]. They also proved to be effective
in adults as a preventive treatment for migraine, showing an improvement in the disease from
the first months of treatment [61]. A recent study described the efficacy of erenumab for the
preventative treatment of migraine in patients with a clinical migraine phenotype following PTH.
Subjects treated with erenumab showed a 95% reduction of headache days without serious adverse
events. Further studies are needed to evaluate the efficacy and safety of erenumab in the treatment of
PTH [62,63].
5. Discussion
Migraine is a primary headache disorder that afflicts millions of subjects, both adults and
adolescents, while PPTH disorder is a common consequence of a TBI event affecting patients’
productivity and quality of life. Recently, many studies tried to understand the pathophysiological and
metabolic mechanisms of PTH. ICHD-3 delineate the classification of PPTH after mTBI, and the clinical
symptoms are not specific and have often been associated with anxiety and depression. FDA does
not approve specific drug treatments for this condition and the development of adverse events or
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MO is very high. Different studies have focused on alterations in the brain structure, especially in
the somatosensory region and the hypothalamus, identified through a magnetic resonance imaging
analysis. The dynamic functional connectivity was significantly correlated with the frequency and
intensity of headache in PPTH and migraine, respectively. Additionally, migraine disease is exacerbated
by visual stimuli as photophobia while stress states intensify PPTH condition. The pathophysiological
mechanisms underlying migraine and PPTH are not yet fully understood, and several data suggest
that migraine and its chronic forms as drug-induced migraine showed altered levels of oxidative
stress biomarkers following a reduction in antioxidant mechanisms. In addition to an increase in
oxidative stress markers, mitochondrial metabolic alterations lead to high levels of lactic acid and a
deficit of both NADH-dehydrogenase and cytochrome-c-oxidase. An increase in neural excitability
at the cortex and trigeminal system levels could lead to an excessive use of migraine drugs and an
increase in the perception of pain. There are really few data in literature regarding PTH acute or
preventive pharmacological medications and, based on the results, the efficacy of the treatment could
not be inferred. The first-choice medications for migraine are NSAIDs drugs but their use should
be limited to avoid medication overuse (MO). Triptans drugs are contraindicated in patients with
vascular or coronary disease due to their vasoconstriction effects while TCAs, used as prophylaxis
medication, are indicated in patients with insomnia and PPTH. A few studies demonstrated that
topiramate could be an effective prophylactic treatment compared to low doses of TCAs. In recent
years, mAbs represented the new frontier of migraine treatment and the preliminary data shows
an efficacy in the reduction of headache in subjects with PPTH treated with erenumab. The use of
mAbs should be careful and carried out considering patients’ features like age, pubertal state and
medical comorbidities.
6. Conclusions
PPTH is an important disorder with a high impact and, although it shows several comorbid
symptoms, currently, there is no specific pharmacological therapy. The results presented in
this review contribute to underline differences and similarities between migraine and PPTH.
Further studies are needed to find targeted treatment and establish both safety and efficacy of
the drugs. Pathophysiology of PTH and biomarkers implicated in the progression of PPTH should
be better investigated. Further studies should consider pools of patients with as few interfering
comorbidities as possible in order to attempt to randomize treatments, whether the latter are to
be considered for acute or preventative management. This would allow a greater clarity on the
therapeutic possibilities available for the therapist, and it would also allow to evaluate the possibility
of different treatment lines both in the pathology free from comorbidity, free from contraindications
and confounding factors, and in the case of comorbidity which may benefit from side effects of any
medications in use. In this way, it would be possible to primarily treat PPTH and, in the same way,
not interfere with any states of depression and/or anxiety, related or not to sleep disturbances.
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